dal-GenE Phase 3 Cardiovascular Precision Medicine Outcomes Trial Results Published in European Heart Journal

July 21, 2022

Trial was negatively impacted by the COVID-19 pandemic and did not meet the primary endpoint. However, the results validate the interaction between dalcetrapib treatment and AA genotype at
variant rs1967309 in the ADCY9 gene.

LONDON and MONTREAL, July 21, 2022 - DalCor Pharmaceuticals announced the results of the dal-GenE Phase 3 cardiovascular precision medicine outcomes trial with publication of ‘Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial’ in the European Heart Journal.1

Read more

World Premiere Performed Simultaneously in Montreal and Quebec City

June 9, 2022

A New Technology Used in Interventional Cardiology

Dr. Réda Ibrahim of the Montreal Heart Institute (MHI) and Dr. Josep Rodés-Cabau of the Quebec Heart and Lung Institute (IUCPQ) simultaneously performed the world’s first use of the SavvyWireTM. This state-of-the-art medical device is designed to support the minimalist approach to transcatheter aortic valve implantation, also known as the TAVI procedure.

Read more

The Montreal Heart Institute leads a Pan-Canadian alliance aimed to improve health outcomes for Canadians living with Heart Failure

May 3, 2022

As the National Heart Failure Awareness Week begins, the Montreal Heart Institute announces the creation of the Canadian Heart Function Alliance (CHF Alliance) Network. Uniting an extensive network of researchers, cardiologists, patients, caregivers, Indigenous elders, policymakers and supporting organizations across the country, this pan-Canadian alliance aims to tackle the challenges of heart failure – a common condition that is often fatal, and on the rise in Canada.

Read more